Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 19OTHER 8NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 4Gastrointestinal 3Sarcoma 2Breast 2Thoracic 1Head & Neck 1Gynecologic 1

Conditions

Stomach Neoplasms 2Neoplasm Metastasis 2Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Breast Neoplasms 1

Interventions

Fluorouracil 126Leucovorin 90Oxaliplatin 82Specimen Handling 71Gemcitabine 61Magnetic Resonance Spectroscopy 55Irinotecan 55Biopsy 53Capecitabine 40Bevacizumab 40Radiotherapy 37Cisplatin 34Cetuximab 29Chemotherapy, Adjuvant 28Erlotinib Hydrochloride 26Neoadjuvant Therapy 21dehydroftorafur 20Cyclophosphamide 19Nivolumab 18Sorafenib 17Radiation 17Paclitaxel 17X-Rays 16Doxorubicin 16aldesleukin 14Immunoglobulin G 14Disulfides 14fludarabine 13Folfox protocol 13Carboplatin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × trastuzumab deruxtecan × Gastrointestinal × Clear all
NCT07619521 2026-06-02

Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
31 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06364410 2026-05-13

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

National Cancer Institute (NCI)

Phase 1 Recruiting
48 enrolled
Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡